SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)
Source: ClinicalTrials.gov NCT03108521 ↗No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glycosylated Hemoglobin A1c (HbA1c) |
6.78 | — |
| SECONDARY Types of Gene Polymorphism |
40.0; 29.2; 40.5; 24.3; 39.2; 25.0 | — |
| SECONDARY Change in Blood Glucose |
-1.60; -2.18; -3.49; -3.45 | — |
| SECONDARY Change in Insulin |
0.66; 4.00; 8.43; 2.99 | — |
| SECONDARY Change in C-peptide |
0.03; 1.11 | — |
Eligibility Criteria
For Sitagliptin group--
Inclusion Criteria
- According to diagnostic criteria from Chinese type 2 diabetes prevention and treatment guidelines in diabetes, that published in the Chinese Medical Association Diabetes credits in 2010: Symptoms of diabetes (polydipsia, polyphagia, polyuria, weight loss, itchy skin, blurred vision and other acute metabolic disorders performance caused by hyperglycemia) and RBG≥11.1mmol/L, or fasting plasma glucose (FPG)≥7.0mmol/L, or plasma glucose of 2 hours post glucose-load≥11.1 and patients diagnosed with type 2 diabetes; HbA1c in the range of 7%-10%;
- Age 40-70 years;
- Body Mass Index(BMI) 18-40;
- Did not accepted any antihyperglycemic therapies during the past 4 weeks, or did not change their antihyperglycemic treatment plan in the past 3 months;
- Did not participate in clinical trials within three months;
- No serious heart, brain, liver and kidney disease;
- Signed informed consent.
Exclusion Criteria
- Have taken any incretin drugs within recent 1 month;
- Patients with a weakened immune system;
- C-peptide < 0.3ng/ml;
- GLP-1 and DPP4-i drugs allergies;
- Pregnancy and breast-feeding patients;
- Patients taking drugs that may affect the metabolism of GLP-1 and DPP4;
- Patients have serious heart, liver, kidney and respiratory dysfunction; Patients have medullary thyroid carcinoma (MTC) with past history or family history, as well as multiple endocrine neoplasia type 2 syndrome (MEN2);
- Drug abusing and alcoholism within a year.
For non-T2D group--
No major diseases such as tumors, no dyslipidemia, chronic diseases such as hypertension, and non-diabetic patients whose blood sugar and glycated hemoglobin values cannot meet the criteria for diagnosis of T2DM, and the age is over 50 years old.
Data sourced from ClinicalTrials.gov (NCT03108521). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.